Flashpoint Therapeutics is developing a new class of cancer immunotherapies through rational nanoscale design of therapeutic architecture to optimize anti-tumor immune response. Across 9 in vivo mouse studies, Flashpoint nanostructures have achieved near curative or curative efficacy using the same therapeutic components that are ineffective in conventional formulations. Flashpoint leverages 20 years of research from the lab of co-founder Dr. Chad Mirkin -- Professor at Northwestern and Director of the International Institute for Nanomedicine, who has founded 3 public or acquired companies and commercialized over 2,000 products. Flashpoint will efficiency move development candidates through clinical testing by leveraging established GMP compliant manufacturing capabilities and FDA approved regulatory paths previously developed to support clinical studies based on components of Flashpoint platform. Flashpoint has assembled an experienced leadership team over core functional areas and is poised to initiate building the company's asset pipeline through partnerships and in-house development.